Abstract
Adenoviruses (AdV) have emerged as important causes of morbidity and mortality in patients after hematopoietic SCT (HSCT). Early diagnosis of the infection by detection of viral DNA may improve the prognosis. A surveillance strategy was evaluated for detection of AdV DNA by PCR in a prospective study of unselected allogeneic HSCT recipients. In parallel with a routine CMV surveillance program, plasma from 20 children and 77 adults was analyzed by quantitative PCR for detection of AdV DNA. In addition, in 12 unselected patients, the presence of AdV-specific T cells were analyzed by enzyme-linked immunosorbent spot (ELISPOT) at 1 to 3 months after transplantation. A total of 5 of 97 (5%) patients had detectable AdV DNA in peripheral blood. Only one patient had high titers and none developed AdV disease. BM as a source of stem cells and myelodysplastic syndrome as the indication for transplantation were independently associated with higher risk of acquiring AdV infection. AdV-specific T cells were detected in 7 (58%) of 12 patients. Although AdV DNA was found in peripheral blood by quantitative PCR in 5% of patients undergoing allogeneic HSCT, the present surveillance program did not have a significant effect on the clinical outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Billings JL, Hertz MI, Wendt CH . Community respiratory virus infections following lung transplantation. Transpl Infect Dis 2001; 3: 138–148.
Emovon OE, Lin A, Howell DN, Afzal F, Baillie M, Rogers J et al. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant 2003; 18: 2436–2438.
Hale GA, Heslop HE, Krance RA, Brenner MA, Jayawardene D, Srivastava DK et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 1999; 23: 277–282.
Hierholzer JC . Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992; 5: 262–274.
Howard DS, Phillips IG, Reece DE, Munn RK, Henslee-Downey J, Pittard M et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999; 29: 1494–1501.
Mori K, Yoshihara T, Nishimura Y, Uchida M, Katsura K, Kawase Y et al. Acute renal failure due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. Bone Marrow Transplant 2003; 31: 1173–1176.
Munoz FM, Piedra PA, Demmler GJ . Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis 1998; 27: 1194–1200.
Walls T, Shankar AG, Shingadia D . Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis 2003; 3: 79–86.
Echavarria M, Forman M, van Tol MJ, Vossen JM, Charache P, Kroes AC . Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358: 384–385.
Gustafson I, Lindblom A, Yun Z, Omar H, Engstrom L, Lewensohn-Fuchs I et al. Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients. J Clin Virol 2008; 43: 79–85.
Schilham MW, Claas EC, van Zaane W, Heemskerk B, Vossen JM, Lankester AC et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002; 35: 526–532.
Bhadri VA, Lee-Horn L, Shaw PJ . Safety and tolerability of cidofovir in high-risk pediatric patients. Transpl Infect Dis 2009; 11: 373–379.
Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619–1627.
Heemskerk B, Lankester AC, van Vreeswijk T, Beersma MF, Claas EC, Veltrop-Duits LA et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191: 520–530.
van Tol MJ, Claas EC, Heemskerk B, Veltrop-Duits LA, de Brouwer CS, van Vreeswijk T et al. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant 2005; 35 (Suppl 1): S73–S76.
Feuchtinger T, Lucke J, Hamprecht K, Richard C, Handgretinger R, Schumm M et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128: 503–509.
Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64–76.
Ljungman P, Ribaud P, Eyrich M, Matthes-Martin S, Einsele H, Bleakley M et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31: 481–486.
Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM . Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 247–254.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O . A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004; 78: 1014–1020.
Feuchtinger T, Lang P, Hamprecht K, Schumm M, Greil J, Jahn G et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32: 282–289.
Baldwin A, Kingman H, Darville M, Foot AB, Grier D, Cornish JM et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1333–1338.
Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M . Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003; 9: 341–352.
Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169: 775–781.
Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, Preuner S et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102: 1114–1120.
Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, Saha V, Shankar AG . Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis 2005; 40: 1244–1249.
Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD . Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312: 529–533.
Suparno C, Milligan DW, Moss PA, Mautner V . Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management. Leuk Lymphoma 2004; 45: 873–885.
Kalpoe JS, van der Heiden PL, Barge RM, Houtzager S, Lankester AC, van Tol MJ et al. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning. Eur J Haematol 2007; 78: 314–321.
Lankester AC, van Tol MJ, Claas EC, Vossen JM, Kroes AC . Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin Infect Dis 2002; 34: 864–867.
Yusuf U, Hale GA, Carr J, Gu Z, Benaim E, Woodard P et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81: 1398–1404.
Avivi I, Chakrabarti S, Milligan DW, Waldmann H, Hale G, Osman H et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10: 186–194.
Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36: 1001–1008.
Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G . Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261–267.
Acknowledgements
We thank all patients, including guardians, for their involvement in the study. We are indebted to Karin Fransson and the staff of the SCT units for their dedication to the study and collection of specimens. We acknowledge the technical and scientific contributions of Annika Allard at the clinical virological laboratory at Umeå University Hospital, Sweden, and the staff at the virological laboratory at Karolinska University Hospital, Huddinge, Sweden. Grants were received from the Stockholm City Council/Karolinska Institutet and from the Swedish Children's Cancer Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Öhrmalm, L., Lindblom, A., Omar, H. et al. Evaluation of a surveillance strategy for early detection of adenovirus by PCR of peripheral blood in hematopoietic SCT recipients: incidence and outcome. Bone Marrow Transplant 46, 267–272 (2011). https://doi.org/10.1038/bmt.2010.86
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.86
Keywords
This article is cited by
-
A survey on incidence and management of adenovirus infection after allogeneic HSCT
Bone Marrow Transplantation (2019)
-
Incidence of Adenoviral DNAemia in Polish Adults Undergoing Allogeneic Haematopoietic Stem Cell Transplantation
Archivum Immunologiae et Therapiae Experimentalis (2015)
-
Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation
Bone Marrow Transplantation (2014)
-
Human parvovirus B19 in pediatric and adult recipients of allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2013)
-
Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation
Annals of Hematology (2012)